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Prior tuberculin skin testing does not boost
QuantiFERON-TB results in paediatric contacts
To the Editors:
We read with interest the paper by LEYTEN et al. [1], which
appeared in the June 2007 issue of the European Respiratory
Journal (ERJ). LEYTEN et al. [1] showed that prior tuberculin skin
tests (TST) do not induce false-positive QuantiFERON1-TB
Gold in-tube (QFT-GIT) assay results when evaluated in the
days immediately following TST administration. In the same
issue of the ERJ, NASEER et al. [2] reported the results of a study
of 10 subjects without risk for tuberculosis infection, who were
tested with QFT-GIT and the T-SPOT.TB assay (Oxford
Immunotec, Abingdon, UK) before, 48 h and 6 weeks after
TST administration. NASEER et al. [2] confirmed the results of
LEYTEN et al. [1] in the first days following skin testing;
however, after 6 weeks, three out of nine individuals turned
from negative to positive with QFT-GIT, and none of the
subjects turned from negative to positive with T-SPOT.TB. On
this basis, NASEER et al. [2] state that there is evidence of
boosting-specific interferon (IFN)-c responses 6 weeks after
TST. According to these results, a high incidence of false-
positive results with QFT-GIT should be expected when the
assay is performed weeks after the skin test. This issue is
potentially very relevant in clinical practice, as current guide-
lines indicate that contacts recently exposed should be tested
for latent infection at the time of diagnosis of the index case
and, if negative, after 8–12 weeks [3]. We therefore retro-
spectively reviewed our series of paediatric contacts to identify
an effect similar to the one reported by NASEER et al. [2].
A total of 70 children received both TST and QuantiFERON1-
TB Gold (QFT-G); 51 (72.9%) were QFT-G negative, nine
(12.8%) were QFT-G positive and 10 (14.3%) were QFT-G
indeterminate (low positive control). After 8–11 weeks, only
one of the 51 initially QFT-G-negative contacts became QFT-G
positive, and the mean values of IFN-c units produced after
stimulation with early secretory antigenic target (ESAT)-6 and
culture filtrate protein (CFP)-10 did not differ before and after
TST (ESAT-6 difference: 0.005 IU?mL-1, p50.745; CFP-10
difference: 0.030 IU?mL-1, p50.453). Of the 10 children with
indeterminate QFT-G results, six tested indeterminate again,
three became negative and one became positive. A total of 81
children were evaluated with TST and QFT-GIT. At the first
visit, 63 (77.8%) contacts were QFT-GIT negative, eight (9.9%)
were QFT-GIT positive and 10 (12.3%) had an undetermined
QFT-GIT. Of those initially negative children, only one became
QFT-GIT positive after TST. The mean IFN-c antigen-specific
production did not change 11 weeks after skin testing (ESAT-6/
CFP-10/TB7.7 difference -0.030 IU?mL-1, p50.281). Of the 10
subjects who were initially indeterminate with QFT-GIT, six
remained indeterminate and four tested negative (table 1).
Interestingly, as already reported in other studies [4, 5],
we detected imperfect agreement between TST and QFT; in
particular, the presence of TST-positive, QFT-negative children
is similar to data recently published in an adult population [6].
Our findings show that among children at risk of acquiring
latent tuberculosis infection after contact with an infectious
index case, there is minimal or no effect on QFT several weeks
after initial skin testing. Only two household contacts became
QFT positive and both were heavily exposed to smear-positive
cases; these QFT conversions could represent true recent
infections, rather than sensitisation to purified protein deriva-
tive. Conversely, such a low rate of QFT conversions might be
considered unexpected, and could be explained by the fact that
at the time of index case diagnosis, most children already had
prolonged contact and therefore may have undergone an
antigen-specific T-cell response. At initial evaluation, ,10% of
contacts were QFT positive.
Our findings are consistent with those reported by LEYTEN et al.
[1] but are in disagreement with those of NASEER et al. [2];
differences in size, demographic and clinical characteristics of
study groups may account for this discrepancy. Our experi-
ence with IFN-c release assays for the diagnosis of latent
tuberculosis supports the concept that prior administration of
TST does not induce false-positive results of the blood tests.
The lack of boosting effect of repeated TST on the enzyme-
linked immunospot-based blood assay has already been
reported in 44 bacille Calmette–Guerin-unvaccinated TST-
negative adult and paediatric contacts repeatedly tested with
the skin and blood assay over a 2-yr period [7]. In that study,
three conversions were observed with TST and none were
observed with the blood assay.
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Overall, our results support the combined use of the skin and
the blood assays, as indicated by recent guidelines [8].
However, it remains to be established whether this strategy
is the most effective for the use of these new promising
diagnostic tests.
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TABLE 1 Results of QuantiFERON1-TB Gold (QFT-G), QuantiFERON1-TB Gold in-tube (QFT-GIT) and tuberculin skin tests (TST)
at initial screening and at time of re-testing
QFT-G QFT-GIT
Negative Positive Indeterminate Negative Positive Indeterminate
M/F 29/22 2/7 4/6 22/41 4/4 6/4
Age yrs 10.5¡4.4 4.6¡3.8 3.2¡3.7 8.9¡6.3 9.2¡4.2 2.5¡1.8
Immigrants from high prevalence countries 14 2 0 11 1 0
BCG vaccinated 15 3 1 14 1 0
Results at initial screening 51 9 10 63 8 10
Results after 8–11 weeks 53 11 6 66 9 6
TST mm at initial screening 1.7¡4.3 8.0¡4.3 0.3¡0.9 1.1¡3.9 8.5¡6.4 0
TST mm after 8–11 weeks 1.7¡4.3 ND 0.6¡1.3 1.4¡3.9 ND 0
TST o5 mm at initial screening 7 8 0 5 6 0
TST o5 mm after 8–11 weeks 8 ND 0 7 ND 0
Data presented as n and mean¡SD. M: male; F: female; BCG: bacille Calmette–Guerin; ND: not done.
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